CSPC Pharmaceutical Group Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSPCY research report →
Price Chart
About the company
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer.
- CEO
- Lei Cai
- IPO
- 2021
- Employees
- 19,700
- HQ
- Shijiazhuang, HE, CN
Get TickerSpark's AI analysis on CSPCY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.86B
- P/E
- 12.20
- PEG
- 0.13
- P/S
- 2.93
- P/B
- 2.40
- EV/EBITDA
- 8.12
- Div Yield
- 3.12%
- Gross Margin
- 71.86%
- Op Margin
- 27.95%
- Net Margin
- 23.73%
- ROE
- 20.68%
- ROIC
- 17.35%
Latest fiscal year · YoY change
- Revenue
- $25.29B-12.8%
- Gross Profit
- $16.59B-18.2%
- Op Income
- $3.86B
- Net Income
- $3.78B-12.7%
- EPS
- $1.32-10.8%
- OCF Growth
- +36.9%
- FCF Growth
- +103.7%
- 52W High
- $5.46
- 52W Low
- $3.26
- 50D MA
- $4.64
- 200D MA
- $4.45
- Beta
- 0.75
- RSI (14)
- 51
- Avg Volume
- 1.38K
No earnings-call transcripts are available for CSPCY yet.
- Free Float
- 100.0%
- Shares Outstanding
- 2.88B
- Float Shares
- 2.88B
Congressional trading
Senate and House stock disclosures for CSPCY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Josh GottheimerHouse · NJ05 | Sell | Sep 15, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jul 14, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jun 13, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Dec 30, 22 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Apr 19, 22 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Mar 15, 22 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jan 10, 22 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Dec 9, 21 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Sep 17, 21 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Apr 13, 21 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Apr 15, 21 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Our CSPCY coverage
Recent articles, reports, and earnings notes.
No research on CSPCY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CSPCY report →AstraZeneca signs CSPC China deal for experimental kidney disease drugs
reuters.com · Jul 2
AstraZeneca obesity tie-up with CSPC seen as shrewd move
proactiveinvestors.co.uk · Jan 30
CSPC Pharmaceutical Group (OTCMKTS:CSPCY) Shares Down 0.5% – Here’s What Happened
defenseworld.net · Dec 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.